The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines

Blood Cells, Molecules, and Diseases

Volumn 48, Issue 1, 2012, Pages 68-75

  Visco, Carlo ^a   Castegnaro, Silvia ^a   Chieregato, Katia ^a   Bernardi, Martina ^a   Albiero, Elena ^a   Zanon, Cristina ^a   Madeo, Domenico ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Ara C; Bendamustine; Cytarabine; Cytotoxic effect; Mantle cell lymphoma; R BAC

Indexed keywords

BENDAMUSTINE; CYTARABINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL METABOLISM; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MITOCHONDRIAL DAMAGE; MITOCHONDRION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTARABINE; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; LYMPHOMA, MANTLE-CELL; MITOCHONDRIA; NITROGEN MUSTARD COMPOUNDS;

ARA; BLASTOIDEA;

EID: 84855206723     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.09.007     Document Type: Article

References (50)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
2. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
3. Ghielmini M., Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476.
4. Jares P., Campo E. Advances in the understanding of mantle cell lymphoma. Br. J. Haematol. 2008, 142:149-165.
5. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 2005, 23:7013-7023.
6. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749-755.
7. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
8. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J. Cancer Res. Clin. Oncol. 2002, 128:603-609.
9. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J. Clin. Oncol. 2008, 26:204-210.
10. Bergmann M.A., Goebeler M.E., Herold M., et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-1364.
11. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2009, 27:4378-4384.
12. Knop S., Straka C., Haen M., et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005, 90:1287-1288.
13. Schoffski P., Seeland G., Engel H., et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann. Oncol. 2000, 11:729-734.
14. Koster W., Heider A., Niederle N., et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J. Thorac. Oncol. 2007, 2:312-316.
15. Schmittel A., Knodler M., Hortig P., et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007, 55:109-113.
16. Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009, 115:473-479.
17. Rummel M.J., von Gruenhagen U., Niederle N., et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2007, 110:385. on behalf of the StiL.
18. Robinson K.S., Williams M.E., Cohen P., et al. Bendamustine HCl (TREANDA™) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: results from phase II multicenter study (SDX-105-02). Blood 2005, 106:923.
19. Gandhi V., Estey E., Keating M.J., Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993, 11:116-124.
20. Chow K.U., Boehrer S., Napieralski S., et al. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk. Lymphoma 2003, 44:165-173.
21. Staib P., Schinkothe T., Dimski T. In vitro modulation of ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine [abstract]. Blood 1999, 94:63.
22. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin. Oncol. 2002, 29:4-11.
23. Zelenin A.V., Poletaev A.I., Stepanova N.G., et al. 7-amino-actinomycin D as a specific fluorophore for DNA content analysis by laser flow cytometry. Cytometry 1984, 5:348-354.
24. Mancaniello D., Carbonari M. Immunophenotyping and DNA content analysis of acetone-fixed cells. Curr. Protoc. Cytom. 2008, 46:9.26.1-9.26.11.
25. Dean P.N., Jett J.H. Mathematical analysis of DNA distributions derived from flow microfluorometry. J. Cell Biol. 1974, 60:523-527.
26. Cossarizza A., Baccarani-Contri M., Kalashnikova G., Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 1993, 197:40-45.
27. Vistica D.T., Skehan P., Scudiero D., et al. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 1991, 51:2515-2520.
28. Berridge M.V., Herst P.M., Tan A.S. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 2005, 11:127-152.
29. Chou T.C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
30. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann. Oncol. 1995, 6:257-262.
31. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
32. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24:4867-4874.
33. Zinzani P.L., Witzig T.E., Vose J.M., et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003). Blood 2008, 112:262.
34. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 2009, 145:344-349.
35. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 2005, 23:5347-5356.
36. Ansell S.M., Inwards D.J., Rowland K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508-514.
37. Hess G., Romaguera J.E., Verhoef G., et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J. Clin. Oncol. 2008, 26:8513.
38. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 2005, 23:3383-3389.
39. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2008, 26:4473-4479.
40. Leoni L.M., Bailey B., Reifert J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 2008, 14:309-317.
41. Chow K.U., Sommerlad W.D., Boehrer S., et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002, 87:33-43.
42. Chow K.U., Boehrer S., Geduldig K., et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001, 86:485-493.
43. Schwanen C., Hecker T., Hubinger G., Wolfle M., Rittgen W., Bergmann L., Karakas T. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002, 16:2096-2105.
44. Gandhi V., Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988, 48:329-334.
45. Gandhi V., Kemena A., Keating M.J., et al. Fludarabine infusion potentiates Arabinosylcytosine lymphocytic leukemia metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992, 52:897-903.
46. Sutoh H., Yamauchi T., Gotoh N., et al. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Anticancer Res. 2003, 23:5037-5042.
47. Bendall H.H., Niemeyer C., Reifert J., et al. Brief exposure to SDX-105 (Treanda™) activates potent apoptosis and cell death in lymphoma and leukemia cells. Proc. Am. Assoc. Cancer Res. 2005, 46:786.
48. Niemeyer C., Bendall H., Bailey B., et al. Mitotic catastrophe induced in cells treated with SDX-105 (Treanda™). Proc. Am. Assoc. Cancer Res. 2005, 46:538.
49. Roué G., Lopez-Guerra M., Milpied P., et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin. Cancer Res. 2008, 14:6907-6915.
50. Visco C., Lissandrini L., Zambello R., et al. Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Ann. Oncol. 2011, 22(4):162-163. abstract 236.